Generic Product News

Published Online: Sunday, March 1, 2009   [ Request Print ]

Azurette (Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol Tablets)

Marketed by:
Watson Pharmaceuticals Inc (Corona, CA)

Compared to:
Mircette (Duramed Pharmaceuticals Inc)

Indication:
December 29, 2008?Watson Pharmaceuticals Inc announced that its subsidiary, Watson Laboratories Inc, received final FDA approval for its abbreviated new drug application for desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP, 0.15 mg/0.02 mg. Desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP is the generic equivalent to Duramed Pharmaceuticals Inc?s Mircette low-dose monthly oral contraceptive product, which is indicated for the prevention of pregnancy.

Dosage Form:
Tablets: each white tablet contains 0.15 mg desogestrel and 0.02 mg ethinyl estradiol; each green tablet contains inert ingredients; each blue tablet contains 0.01 mg ethinyl estradiol.

For More Information:
www.watson.com

---

Cefadroxil Capsules, 500 mg

Marketed by:
Greenstone LLC (Peapack, NJ)

Compared to:
Duricef (Warner Chilcott)

Indication:
December 11, 2008?Greenstone LLC, Pfizer?s generic subsidiary, introduced Cefadroxil Capsules, 500 mg to its product line. Cefadroxil capsules are indicated for the treatment of patients with infection caused by susceptible strains of organisms in the following diseases: urinary tract infections, skin and skin structure infections, and pharyngitis and/or tonsillitis. The capsules are contraindicated in patients with known allergy to the cephalosporin group of antibiotics.

Dosage Form:
Capsules: 500 mg

For More Information:
www.greenstonellc.com

---

Fentanyl Transdermal System, CII

Marketed by:
Teva Pharmaceuticals (North Wales, PA)

Compared to:
Duragesic Transdermal System (Johnson & Johnson Corp)

Indication:
October 23, 2008?Teva Pharmaceuticals announced the introduction and availability of Fentanyl Transdermal System, CII. This product is AB-rated to Duragesic Transdermal System. It is indicated for the management of persistent, moderate-to-severe chronic pain that requires continuous opioid administration for an extended period of time and cannot be managed by other means, such as nonsteroidal analgesics, opioid combination products, or immediate-release opioids. Doses must be individualized based on the status of each patient and should be assessed at regular intervals after application.

Dosage Form:
25, 50, 75, and 100 mcg/hour

For More Information:
www.tevausa.com
888-TEVA USA (888-838-2872)

---

Kionex (Sodium Polystyrene Sulfonate Suspension, USP) 15 g/60 mL

Marketed by:
Paddock Laboratories Inc (Minneapolis, MN)

Compared to:
SPS Suspension (Carolina Medical Products)

Indication:
December 30, 2008?Paddock Laboratories Inc announced the launch of Kionex 15 g/60 mL, which is AA-rated to SPS Suspension. This product is indicated for the treatment of hyperkalemia. Kionex can be administered orally or in an enema. The average adult dose is 15 g (60 mL) to 60 g (240 mL) of suspension. This is best provided by administering 15 g of Kionex suspension 1 to 4 times daily.

Dosage Form:
480 mL and unit-dose 60 mL

For More Information:
www.paddocklabs.com
800-328-5113